Specialist Updates 
Cardiology

SGLT2 inhibitor improves CV outcomes in severe heart failure

The benefit was seen regardless of the presence of type 2 diabetes, researchers say
Medicom Staff writer
0
2 September 2020
Save

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020

The SGLT2 inhibitor empagliflozin is associated with a reduced risk of hospitalisation and death in patients who have heart failure with reduced ejection fraction (HFrEF), researchers have found.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .